Dolutegravir : Antiretroviral Drug
Resistance to the antiretroviral drug dolutegravir (DTG) is increasing among HIV patients, a new report by the World Health Organization (WHO) highlighted.
- Dolutegravir (DTG) is an antiviral drug used with other medications to treat human immunodeficiency virus (HIV) infection, the virus that can cause the acquired immunodeficiency syndrome (AIDS).
- Dolutegravir is in a class of medications called HIV integrase inhibitors.
- It works by decreasing the amount of HIV in your blood and increasing the number of immune cells.
- Although dolutegravir does not cure HIV, using it along with other medications may decrease your chance of developing AIDS and HIV-related illnesses such as serious infections or cancer.
- WHO has recommended the use of dolutegravir as the preferred first- and second-line HIV treatment for all population groups.
- It is more effective, easier to take and has fewer side effects than other drugs currently in use.
